An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

An anti-inflammatory liquid composition for covering oral mucosa includes: a rosin; a shellac; and a solvent. A content of the rosin is 1 wt % or more and 15 wt % or less relative to a total amount of the composition. A content of the shellac is 35 wt % or more and 45 wt % or less relative to the total amount of the composition. A total content of the rosin, the shellac, and a copal is 45 wt % or more and 55 wt % or less relative to the total amount of the composition.

The present invention relates to a composition having an anti-glycation effect and an application thereof. The anti-glycation composition includes the following constituents in parts by mass: 0.1 to 5 parts of Osmanthus fragrans extract, 0.1 to 5 parts of Punica granatum extract and 0.1 to 2 part of Olea europaea extract, wherein in the Osmanthus fragrans extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of verbascoside is more than or equal to 10%; in the Punica granatum extract, a mass content of polyphenol is more than or equal to 30%, and a mass content of punicalagin is more than or equal to 8%; and in the Olea europaea extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of hydroxytyrosol is more than or equal to 3%.

The present invention relates to a composition having an anti-glycation effect and an application thereof. The anti-glycation composition includes the following constituents in parts by mass: 0.1 to 5 parts of Osmanthus fragrans extract, 0.1 to 5 parts of Punica granatum extract and 0.1 to 2 part of Olea europaea extract, wherein in the Osmanthus fragrans extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of verbascoside is more than or equal to 10%; in the Punica granatum extract, a mass content of polyphenol is more than or equal to 30%, and a mass content of punicalagin is more than or equal to 8%; and in the Olea europaea extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of hydroxytyrosol is more than or equal to 3%.

The present disclosure relates to a medicinal composition and related methods using Lawsone (2-hydroxy-1,4-naphthoquinone) as a key active ingredient for treating pain associated with chemotherapy-induced palmar plantar erythrodysesthesia (Hand-Foot Syndrome). The medicinal composition may be administered topically as a gel, ointment, cream, lotion, suspension, spray, transdermal patch or liquid alone or in combination with other topical steroids, topical NSAIDS, antiarrhythmics, moisturizers, capsaicin, emollients, herbal remedies and essential or carrier oils. The medicinal composition eliminates the pain and burning sensation experienced with palmar-plantar erythrodysesthesia and allows patients to carry on with normal daily activities after a session of chemotherapy.

The present disclosure relates to a medicinal composition and related methods using Lawsone (2-hydroxy-1,4-naphthoquinone) as a key active ingredient for treating pain associated with chemotherapy-induced palmar plantar erythrodysesthesia (Hand-Foot Syndrome). The medicinal composition may be administered topically as a gel, ointment, cream, lotion, suspension, spray, transdermal patch or liquid alone or in combination with other topical steroids, topical NSAIDS, antiarrhythmics, moisturizers, capsaicin, emollients, herbal remedies and essential or carrier oils. The medicinal composition eliminates the pain and burning sensation experienced with palmar-plantar erythrodysesthesia and allows patients to carry on with normal daily activities after a session of chemotherapy.

The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.

The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.

The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.

The present invention discloses a medicine for treatment or adjuvant treatment of acquired immunodeficiency syndrome, a preparation method thereof and use methods thereof. The medicine comprises: lightyellow sophora root, glabrous greenbrier rhizome, bark of Chinese corktree, raw sessile stemona root, alumen, coptis root, cortex dictamni, chinaberry bark and root-bark, pangolin scales, amber, eucommia bark, tree peony bark, clematis root, common cnidium fruit, Chinese angelica, licorice root, common macrocarpium fruit, barbary wolfberry fruit, medicinal indianmulberry root, cherokee rose fruit, chinaroot greenbier rhizome, akebia fruit, milkvetch root, Japanese climbing fern spore, asiatic pennywort herb, mulberry leaf and frankincense. The present invention not only provides the medicine capable of effectively treating the acquired immunodeficiency syndrome, but also enables the medicine to be capable of being used in conjunction with other medical technical means to easily achieve a more ideal treatment effect.